상피성 난소암의 공고/유지 요법의 최신 지견

참고문헌 (97)

1. "Epidemiological and molecular aspects of ovarian cancer risk", 127, pp.73~9 (2001)
2. "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer", pp.1~6 (1996)
3. "Up date in the management of advanced ovarian carcinoma", 32, pp.49~58 (1999)
4. "Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer", 92, pp.699~708 (2000)
5. "Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer", 18, pp.3084~92 (2000)
6. "Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer", 18, pp.106~15 (2000)
7. "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer", 21, pp.3194~200 (2003)
8. "A randomized clinical trial of cisplatin", paclitaxel versus carboplatin, pp.2003, 95[DOI]
9. "Remaining controversies in the upfront management of advanced ovarian cancer", 14, pp.707~20 (2004)
10. "Analysis of failures after negative second-look in patients with advanced ovarian cancer", 68, pp.150~5 (1998), an Italian multicenter study
11. "Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma", pp.274~82 (1988)
12. "Current controversies in ovarian cancer maintenance chemotherapy and neoadjuvant chemotherapy as standard care American Society of Clinical Oncology", pp.268~75 (2004)
13. "Ovarian cancer treatment: what is new.", 13(2), pp.241~50 (2003)
14. "Treatment of advanced ovarian cancer with surgery and consolidation of response by whole-abdominal radiotherapy", pp.40~7 (1988)
15. "Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma", pp.509~16 (1988)
16. "Whole abdominal irradiation following chemotherapy in advanced ovarian carcinoma", rubi(v r), pp.273~9 (1988)
17. "Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin", cyclophosphamide therapy and second-look laparotomy, 1988, 327~32
18. "Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look", pp.392~5 (1990)
19. "Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer"
20. "A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer", pp.440~8 (1993)
21. "Treatment of ovarian cancer with surgery", 7, pp.65~70 (1996)
22. "The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery", 74, pp.400~7 (1999)
23. "Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma", 75, pp.62~7 (1999)
24. "Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer", 72, pp.215~9 (1999)
25. "First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer", 90, pp.8~15 (2003)
26. "The role of radiation therapy in the management of ovarian cancer Controversial in management", pp.219~42 (1998)
27. "Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer?", pp.97~103 (1993)
28. "Consolidation treatment of advanced ovarian carcinoma in complete surgical remission after induction chemotherapy", 13, pp.278~286 (2003)
29. "Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer" (1988)
30. "Intraperitoneal P-32 after negative second-look laparotomy in ovarian carcinoma", pp.2434~7 (1989)
31. "Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary", pp.146~9 (1992)
32. "32P following negative second- look laparotomy for epithelial ovarian cancer", pp.141~6 (1993)
33. "Use of P-32 in stage III epithelial carcinoma of the ovary", spa(s jr wj), pp.35~9 (1994)
34. "Consolidative 32P after second-look laparotomy for ovarian carcinoma", 6, pp.97~102 (1998)
35. "De Vos LN and Trop CG Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma Analysis of 313 patients treated primarily or at second-look laparotomy", pp.2250~60 (1993)
36. "versus observation after negative second- look laparotomy for stage III ovarian carcinoma a randomized trial of the Gynecologic Oncology Group", 21, pp.2849~55 (2003)
37. "Intraperitoneal radioactive chromic phosphate p32 in the treatment of ovarian cancer", 80, pp.1513~7 (1987)
38. "Phosphorous-32-chromic phosphate for ovarian cancer Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy", 36, pp.29~36 (1995)
39. "Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies"
40. "Intraperitoneal radioimmunotherapy for ovarian cancer", pp.529~36 (1989)
41. "Radioimmunotherapy of ovarian cancer"
42. "A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma", 10, pp.3249~3253 (1999), Clin Cancer Res 10
43. "Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer", 5, pp.223~6 (1998)
44. "Phase I study of 90Y-labeled B72 3 intraperitoneal administration in patients with ovarian cancer effect of dose and EDTA coadministration on pharmacokinetics and toxicity", 5, pp.953~61 (1999), Clin Cancer Res 5
45. "Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer", 41, pp.1168~76 (2000)
46. "Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy", 10, pp.44~6 (2000)
47. "A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549", 23, pp.449~5008 (2004)
48. "Radioimmunotherapy in advanced ovarian cancer is there a role for pre-targeting with 90Y-biotin?", 93, pp.691~8 (2004)
49. "Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer", 335, pp.1950~5 (1996)
50. "Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma an intergroup study of the Gynecologic Oncology Group", 19, pp.1001~7 (2001)
51. "Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer a randomized trial of the Gruppo Oncologico Nord-Ovest", 76, pp.157~62 (2000)
52. "Intraperitoneal cisplatin-based chemotherapy versus intravenous cisplatin- based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer", 72, pp.55~60 (2001)
53. "Randomized phase III study of intravenous cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer", 21, pp.~172 803 (2002)
54. "Intraperitoneal cisplatin and etoposide in the treatment of refractory", recurrent ovarian carcinoma, 1989, 1327~32
55. "Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission", pp.222~5 (1992)
56. "Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy", pp.7~11 (1992)
57. "Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy", pp.287~90 (1993)
58. "Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission"
59. "A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment", 69, pp.17~22 (1998)
60. "Intraperitoneal chemotherapy for ovarian carcinoma results of long-term follow-up", 20, pp.694~8 (2002)
61. "Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission", 91, pp.341~5 (2003)
62. "Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer results of a phase I", II trial, 2004, pp.10, 2962~7[DOI]
63. "Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer Consolidative intraperitoneal cisplatin in ovarian cancer", 92, pp.147~51 (2004)
64. "Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second look laparotomy A reassessment based on mature data", pp.272~6 (1994)
65. "8-year results of EORTC 55875 a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy", 13, pp.196~203 (2003)
66. "High-dose chemotherapy with autologous transplantation for persistent", relapsed ovarian cancer a multivariate analysis of survival for 100 consecutively treated patients, 1997, pp.15, 1309~17
67. "High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer", 133, pp.504~15 (2000)
68. "Randomized phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse", 94, pp.98~106 (2004)
69. "High-dose chemotherapy with hematopoietic rescue in patients with stage III-IV ovarian cancer", 15, pp.1302~8 (1997)
70. "Phase III randomized trial of high-dose chemotherapy support as consolidation therapy for patients preliminary results of a GINECO", FNCLCC, pp.2001, 20[DOI]
71. "Phase III randomized trial of high-dose chemotherapy support as consolidation in patients 5-year follow-up of a GINECO", FNCLCC, pp.2004, 23[DOI]
72. "Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide and cisplatin in advanced ovarian carcinoma", 45, pp.284~9 (1992)
73. "A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide and cisplatin in advanced epithelial ovarian cancer", pp.30~36 (1993)
74. "A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma", 8, pp.327~33 (1997)
75. "Dose-effect study of carboplatin in ovarian cancer:a Danish Ovarian Cancer Group Study", 15, pp.193~8 (1997)
76. "High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer:a randomized study of the Gruppo Oncologico Nord-Ovest", 14, pp.351~6 (1996)
77. "Consolidation therapy revisited: intravenous chemotherapy", 13, pp.204~7 (2003)
78. "Follow-up of Memorial- Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103:paclitaxel in refractory ovarian cancer", 14, pp.796~9 (1996)
79. "Sequential Hycamtin following paclitaxel and carboplatin in advanced ovarian cancer" (1999)
80. "Weekly paclitaxel and carboplatin followed by topotecan as first-line therapy for patients with advanced epithelial ovarian cancer", 20, pp.215~ (2001)
81. "GOG 182 study. Protocol available at" (2003)
82. "Phase 3 randomized trial of 12 versus 3 months of single agent paclitaxel inpatients with advanced ovarian cancer who attained a clinically-defined complete response to platinum", paclitaxel-based chemotherapy:a Southwest Oncology Group and Gynecologic Oncology Group trial, 2003, pp.21, 2460~5
83. "Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer", 82, pp.317~22 (2001)
84. "A phase III trial of consolidation versus NIHIL", 21, pp.204~812 (2002)
85. "paclitaxel", carboplatin followed by topotecan in first- line treatment of ovarian cancer FIGO stages IIb-IV Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO, 2003, pp.22, 446~1793
86. "Topotecan compared with no therapy after response to surgery and carboplatin", paclitaxel in patients with ovarian cancer Multicenter Italian Trials in Ovarian Cancer, 2004, pp.22, 2635~1 42
87. "Second-line treatment and consolidation therapies in advanced ovarian cancer", 11, pp.52~6 (2001)
88. "Randomized phase III trial of observation versus six courses of single agent paclitaxel in patients with advanced ovarian cancer who attained a complete response to platinum", paclitaxel-based chemotherapy Ninth Biennial Meeting of the International Gynecologic Cancer Society, 2002, 83~24 8
89. "Weekly paclitaxel as consolidation treatment in patients with advanced ovarian cancer who attained a pathological", 12, pp.561~ (2002), an Italian phase II multicenter study
90. "Consolidation therapies revisited: weekly paclitaxel", 13, pp.208~11 (2003)
91. "Weekly paclitaxel in the management of ovarian cancer", 27, pp.37~40 (2000)
92. "Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug- resistant cancer", 60, pp.1878~86 (2000)
93. "An International Multicentre phase III study of BAY 12-9566 versus placebo in patients responsive to primary surgery", paclitaxel + platinum containing chemotherapy, 2001, pp.20, 211~843
94. "Maintenance treatment with interferon for advanced ovarian cancer results of the Northern and Yorkshire gynaecology group randomised phase III study", 91, pp.621~6 (2004)
95. "Intraperitoneal interferon-α in residual ovarian carcinoma", 75, pp.10~4 (1999)
96. "Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look a prospective randomized trial of 111 patients", 65, pp.499~505 (1997)
97. "placebo- controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer", 22, pp.3507~16 (2004)

관련 논문AI추천